

Delacourte A. Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease. *Acta neuropathologica*. 1996;91(4):351-9.

[24] Sergeant N, Wattez A, Delacourte A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms. *J Neurochem*. 1999;72(3):1243-9.

[25] Togo T, Sahara N, Yen SH, Cookson N, Ishizawa T, Hutton M, de Silva R, Lees A, Dickson DW. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. *J Neuropathol Exp Neurol*. 2002;61(6):547-56.

[26] Delacourte A, Robitaille Y, Sergeant N, Buee L, Hof PR, Wattez A, Laroche-Cholette A, Mathieu J, Chagnon P, Gauvreau D. Specific pathological Tau protein variants characterize Pick's disease. *J Neuropathol Exp Neurol*. 1996;55(2):159-68.

[27] Delacourte A, Sergeant N, Wattez A, Gauvreau D, Robitaille Y. Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation. *Ann Neurol*. 1998;43(2):193-204.

[28] Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. *Neuron*. 1992;8(1):159-68.

[29] Scaravilli T, Tolosa E, Ferrer I. Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting. *Mov Disord*. 2005;20 Suppl 12:S21-8.

[30] Komori T, Arai N, Oda M, Nakayama H, Mori H, Yagishita S, Takahashi T, Amano N, Murayama S, Murakami S, Shibata N, Kobayashi M, Sasaki S, Iwata M. Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy. *Acta neuropathologica*. 1998;96(4):401-8.

[31] Josephs KA, Dickson DW. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. *Mov Disord*. 2003;18(9):1018-26.

[32] Osaki Y, Ben-Shlomo Y, Lees AJ, Daniel SE, Colosimo C, Wenning G, Quinn N. Accuracy of clinical diagnosis of progressive supranuclear palsy. *Mov Disord*. 2004;19(2):181-9.

[33] Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, Holton JL, Revesz T, Lees AJ. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. *Brain*. 2005;128(Pt 6):1247-58.

[34] Tsuboi Y, Josephs KA, Boeve BF, Litvan I, Caselli RJ, Caviness JN, Uitti RJ, Bott AD, Dickson DW. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. *Mov Disord*. 2005;20(8):982-8.

[35] Mochizuki A, Ueda Y, Komatsuzaki Y, Tsuchiya K, Arai T, Shoji S. Progressive

supranuclear palsy presenting with primary progressive aphasia--clinicopathological report of an autopsy case. *Acta neuropathologica*. 2003;105(6):610-4.

[36] Josephs KA, Boeve BF, Duffy JR, Smith GE, Knopman DS, Parisi JE, Petersen RC, Dickson DW. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. *Neurocase*. 2005;11(4):283-96.

[37] Karnik NS, D'Apuzzo M, Greicius M. Non-fluent progressive aphasia, depression, and OCD in a woman with progressive supranuclear palsy: neuroanatomical and neuropathological correlations. *Neurocase*. 2006;12(6):332-8.

[38] Daniel SE, de Bruin VM, Lees AJ. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. *Brain*. 1995;118 ( Pt 3):759-70.

[39] Rebeiz JJ, Kolodny EH, Richardson EP, Jr. Corticodentatonigral degeneration with neuronal achromasia. *Arch Neurol*. 1968;18(1):20-33.

[40] Constantinidis J, Richard J, Tissot R. Pick's disease. Histological and clinical correlations. *European neurology*. 1974;11(4):208-17.

[41] Mesulam MM. Primary progressive aphasia--differentiation from Alzheimer's disease. *Ann Neurol*. 1987;22(4):533-4.

[42] Lippa CF, Smith TW, Fontneau N. Corticonigral degeneration with neuronal achromasia. A clinicopathologic study of two cases. *J Neurol Sci*. 1990;98(2-3):301-10.

[43] Lippa CF, Cohen R, Smith TW, Drachman DA. Primary progressive aphasia with focal neuronal achromasia. *Neurology*. 1991;41(6):882-6.

[44] Murayama S, Saito Y, Kanemaru K, Tokumaru A, Ishii K, Sawabe M. [Establishment of brain bank for aging research]. *Nippon Ronen Igakkai zasshi*. 2005;42(5):483-9.

[45] McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. *Neurology*. 1996;47(5):1113-24.

[46] McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. *J Alzheimers Dis*. 2006;9(3 Suppl):417-23.

[47] Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta*

Neuropathol (Berl). 1991;82(4):239-59.

[48] Braak H, Alafuzoff I, Arzberger T, Kretschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol (Berl)*. 2006;112(4):389-404.

[49] Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Heyman A. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. *Neurology*. 1989;39(9):1159-65.

[50] Yamaguchi H, Haga C, Hirai S, Nakazato Y, Kosaka K. Distinctive, rapid, and easy labeling of diffuse plaques in the Alzheimer brains by a new methenamine silver stain. *Acta Neuropathol (Berl)*. 1990;79(5):569-72.

[51] Gallyas F. Silver staining of Alzheimer's neurofibrillary changes by means of physical development. *Acta morphologica Academiae Scientiarum Hungaricae*. 1971;19(1):1-8.

[52] Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, Iwatsubo T, Murayama S. Accumulation of phosphorylated alpha-synuclein in aging human brain. *J Neuropathol Exp Neurol*. 2003;62(6):644-54.

[53] Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. *Nature cell biology*. 2002;4(2):160-4.

[54] Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. *Neurosci Lett*. 1995 Apr 21;189(3):167-9.

[55] Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. *J Neurosci Res*. 1997;48(2):128-32.

[56] de Silva R, Lashley T, Strand C, Shiarli AM, Shi J, Tian J, Bailey KL, Davies P, Bigio EH, Arima K, Iseki E, Murayama S, Kretschmar H, Neumann M, Lippa C, Halliday G, MacKenzie J, Ravid R, Dickson D, Wszolek Z, Iwatsubo T, Pickering-Brown SM, Holton J, Lees A, Revesz T, Mann DM. An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. *Acta Neuropathol (Berl)*. 2006;111(4):329-40.

[57] Ishizawa T, Ko LW, Cookson N, Davies P, Espinoza M, Dickson DW. Selective neurofibrillary degeneration of the hippocampal CA2 sector is associated with four-repeat tauopathies. *J Neuropathol Exp Neurol*. 2002;61(12):1040-7.

[58] Otvos L, Jr., Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM. Monoclonal antibody

- PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. *J Neurosci Res.* 1994;39(6):669-73.
- [59] Hasegawa M, Jakes R, Crowther RA, Lee VM, Ihara Y, Goedert M. Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. *FEBS Lett.* 1996;384(1):25-30.
- [60] Murayama S, Saito Y. Neuropathological diagnostic criteria for Alzheimer's disease. *Neuropathology.* 2004;24(3):254-60.
- [61] Saito Y, Ruberu NN, Sawabe M, Arai T, Kazama H, Hosoi T, Yamanouchi H, Murayama S. Lewy body-related alpha-synucleinopathy in aging. *J Neuropathol Exp Neurol.* 2004;63(7):742-9.
- [62] Saito Y, Ruberu NN, Sawabe M, Arai T, Tanaka N, Kakuta Y, Yamanouchi H, Murayama S. Staging of argyrophilic grains: an age-associated tauopathy. *J Neuropathol Exp Neurol.* 2004;63(9):911-8.
- [63] Jellinger KA. Dementia with grains (argyrophilic grain disease). *Brain Pathol.* 1998;8(2):377-86.
- [64] Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, L. Amaducci, J.-M. Orgogozo, A. Brun, A. Hofman, D. M. Moody, M. D. O'Brien, T. Yamaguchi, J. Grafman, B. P. Drayer, D. A. Bennett, M. Fisher, J. Ogata, E. Kokmen, F. Bermejo, P. A. Wolf, P. B. Gorelick, K. L. Bick, A. K. Pajean, M. A. Bell, C. DeCarli, A. Culebras, A. D. Korczyn, J. Bogousslavsky, A. Hartmann, and P. Scheinberg. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. *Neurology.* 1993;43(2):250-60.
- [65] Saito Y, Yamazaki M, Kanazawa I, Murayama S. Severe involvement of the ambient gyrus in a case of dementia with argyrophilic grain disease. *J Neurol Sci.* 2002;196(1-2):71-5.
- [66] Josephs KA, Mandrekar JN, Dickson DW. The relationship between histopathological features of progressive supranuclear palsy and disease duration. *Parkinsonism & related disorders.* 2006;12(2):109-12.
- [67] Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *Journal of psychiatric research.* 1975;12(3):189-98.
- [68] Hasegawa K, IK MK. An investigation of dementia rating scale for the elderly. *Seishin Igaku.* 1974;16:965-69.
- [69] Katoh S, SH, Onodera A., Ueda H., Oikawa K., Ikeda K., Kosaka A., Imai Y., Hasegawa

- K. Development of the revised version of Hasegawa's dementia scale (HDS-R). *Rounen Seishinigaku Zasshi*. 1991;2(11):1339-47.
- [70] Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. *The Gerontologist*. 1969;9(3):179-86.
- [71] Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. *Br J Psychiatry*. 1982;140:566-72.
- [72] Maher ER, Lees AJ. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). *Neurology*. 1986;36(7):1005-8.
- [73] Verny M, Jellinger KA, Hauw JJ, Bancher C, Litvan I, Agid Y. Progressive supranuclear palsy: a clinicopathological study of 21 cases. *Acta neuropathologica*. 1996;91(4):427-31.
- [74] De Bruin VM, Lees AJ. Subcortical neurofibrillary degeneration presenting as Steele-Richardson-Olszewski and other related syndromes: a review of 90 pathologically verified cases. *Mov Disord*. 1994;9(4):381-9.
- [75] Collins SJ, Ahlskog JE, Parisi JE, Maraganore DM. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. *J Neurol Neurosurg Psychiatry*. 1995;58(2):167-73.
- [76] 葛原茂樹 山, 豊倉康夫, 嶋田裕之, 吉村正博, 森秀生, 水谷俊雄. 進行性核上性麻痺の臨床症状の検討. 厚生省特定疾患・神経変性疾患調査研究班・1989年度研究報告書. 1990:117-20.
- [77] 長友秀樹. 進行性核上性麻痺の臨床病理学的研究. *横浜医学*. 1992;43:335-46.
- [78] 天野直二 小阪憲司. 非アルツハイマー型変性痴呆. 進行性核上性麻痺の痴呆. *老年精神医学雑誌*. 1993;4:1129-35.
- [79] Litvan I, Mangone CA, McKee A, Verny M, Parsa A, Jellinger K, D'Olhaberriague L, Chaudhuri KR, Pearce RK. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. *J Neurol Neurosurg Psychiatry*. 1996;60(6):615-20.
- [80] Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical Parkinsonism. *J Neurol Neurosurg Psychiatry*. 2007: [Epub ahead of print]
- [81] Tolnay M, Schwieter M, Monsch AU, Staehelin HB, Langui D, Probst A. Argyrophilic grain disease: distribution of grains in patients with and without dementia. *Acta neuropathologica*. 1997;94(4):353-8.

- [82] Jellinger KA, Bancher C. Senile dementia with tangles (tangle predominant form of senile dementia). *Brain Pathol.* 1998;8(2):367-76.
- [83] Jellinger KA, Attems J. Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease. *Acta Neuropathol (Berl).* 2007;113(2):107-17.
- [84] Braak H, Braak E. Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria. *J Neural Transm.* 1998;105(8-9):801-19.
- [85] Ikeda K, Akiyama H, Arai T, Matsushita M, Tsuchiya K, Miyazaki H. Clinical aspects of argyrophilic grain disease. *Clinical neuropathology.* 2000;19(6):278-84.
- [86] Saito Y, Murayama S. Neuropathology of mild cognitive impairment. *Neuropathology.* 2007;27(6):578-84.
- [87] Fujino Y, Wang DS, Thomas N, Espinoza M, Davies P, Dickson DW. Increased frequency of argyrophilic grain disease in Alzheimer disease with 4R tau-specific immunohistochemistry. *J Neuropathol Exp Neurol.* 2005;64(3):209-14.
- [88] Miserez AR, Clavaguera F, Monsch AU, Probst A, Tolnay M. Argyrophilic grain disease: molecular genetic difference to other four-repeat tauopathies. *Acta neuropathologica.* 2003;106(4):363-6.
- [89] 饗場郁子 齋, 奥田聡, 吉田眞理, 橋詰良夫. 剖検例からみた進行性核上性麻痺臨床像. *神経内科.* 2002;56(2):143-9.
- [90] Jellinger K, Riederer P, Tomonaga M. Progressive supranuclear palsy: clinico-pathological and biochemical studies. *Journal of neural transmission.* 1980(16):111-28.
- [91] Albert ML, Feldman RG, Willis AL. The 'subcortical dementia' of progressive supranuclear palsy. *J Neurol Neurosurg Psychiatry.* 1974;37(2):121-30.
- [92] Blin J, Baron JC, Dubois B, Pillon B, Cambon H, Cambier J, Agid Y. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. *Arch Neurol.* 1990;47(7):747-52.
- [93] Lees AJ. The Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). *Mov Disord.* 1987;2:272-87.
- [94] 湯浅龍彦. 「神経疾患の予防・診断・治療に関する臨床研究班」報告書. 2002.
- [95] Braak H, Jellinger K, Braak E, Bohl J. Allocortical neurofibrillary changes in progressive supranuclear palsy. *Acta Neuropathol (Berl).* 1992;84(5):478-83.
- [96] Bigio EH, Brown DF, White CL 3rd. Progressive supranuclear palsy with dementia: cortical pathology. *J Neuropathol Exp Neurol.* 1999;58(4):359-64.
- [97] Bigio EH, Vono MB, Satumtira S, Adamson J, Sontag E, Hynan LS, White CL 3rd, Baker

- M, Hutton M. Cortical synapse loss in progressive supranuclear palsy. *J Neuropathol Exp Neurol*. 2001;60(5):403-10.
- [98] Vermersch P, Robitaille Y, Bernier L, Watzel A, Gauvreau D, Delacourte A. Biochemical mapping of neurofibrillary degeneration in a case of progressive supranuclear palsy: evidence for general cortical involvement. *Acta Neuropathol (Berl)*. 1994;87(6):572-7.
- [99] Takahashi M, Weidenheim KM, Dickson DW, Ksiezak-Reding H. Morphological and biochemical correlations of abnormal tau filaments in progressive supranuclear palsy. *J Neuropathol Exp Neurol*. 2002;61(1):33-45.
- [100] Tomonaga M. Ultrastructure of neurofibrillary tangles in progressive supranuclear palsy. *Acta Neuropathol (Berl)*. 1977;37(2):177-81.
- [101] Saito Y, Motoyoshi Y, Kashima T, Izumiyama-Shimomura N, Toda T, Nakano I, et al. Unique Tauopathy in Fukuyama-Type Congenital Muscular Dystrophy. *J Neuropathol Exp Neurol*. 2005;64(12):1118-26.
- [102] Arai T, Ikeda K, Akiyama H, Nonaka T, Hasegawa M, Ishiguro K, Iritani S, Tsuchiya K, Iseki E, Yagishita S, Oda T, Mochizuki A. Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. *Ann Neurol*. 2004;55(1):72-9.
- [103] Tomonaga M. [On the morphological changes of locus caeruleus in the senile human brain (author's transl)]. *Nippon Ronen Igakkai zasshi*. 1979;16(6):545-50.
- [104] Arendt T, Bigl V, Arendt A, Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease. *Acta Neuropathol (Berl)*. 1983;61(2):101-8.
- [105] Braak E, Braak H, Mandelkow EM. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. *Acta neuropathologica*. 1994;87(6):554-67.
- [106] Su JH, Cummings BJ, Cotman CW. Early phosphorylation of tau in Alzheimer's disease occurs at Ser-202 and is preferentially located within neurites. *Neuroreport*. 1994;5(17):2358-62.
- [107] de Silva R, Lashley T, Gibb G, Hanger D, Hope A, Reid A, Bandopadhyay R, Utton M, Strand C, Jowett T, Khan N, Anderton B, Wood N, Holton J, Revesz T, Lees A. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. *Neuropathol Appl Neurobiol*. 2003;29(3):288-302.
- [108] Cordato NJ, Pantelis C, Halliday GM, Velakoulis D, Wood SJ, Stuart GW, Currie J, Soo

- M, Olivieri G, Broe GA, Morris JG. Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. *Brain*. 2002;125(Pt 4):789-800.
- [109] Magherini A, Litvan I. Cognitive and behavioral aspects of PSP since Steele, Richardson and Olszewski's description of PSP 40 years ago and Albert's delineation of the subcortical dementia 30 years ago. *Neurocase*. 2005;11(4):250-62.
- [110] Lecours AR, Lehrmitte, F. The "Pure Form" of the phonetic disintegration syndrome (pure anarthria); anatomo-clinical report of a historical case. *Brain and language*. 1976;3(1):88-113.
- [111] Saito Y, Kita Y, Bando M, Nagura H, Yamanouchi H, Ishii K. [Neuropsychological analysis in 2 cases of infarction in the left precentral gyrus--with special reference to apraxia of speech and agraphia]. *Rinsho Shinkeigaku*. 1997;37(6):487-91.
- [112] Hillis AE, Work M, Barker PB, Jacobs MA, Breese EL, Maurer K. Re-examining the brain regions crucial for orchestrating speech articulation. *Brain*. 2004;127(Pt 7):1479-87.
- [113] Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. *Ann Neurol*. 2006;59(1):156-65.
- [114] Boeve B, Dickson D, Duffy J, Bartleson J, Trenerry M, Petersen R. Progressive nonfluent aphasia and subsequent aphasic dementia associated with atypical progressive supranuclear palsy pathology. *European neurology*. 2003;49(2):72-8.
- [115] Oba H, Yagishita A, Terada H, Barkovich AJ, Kutomi K, Yamauchi T, Furui S, Shimizu T, Uchigata M, Matsumura K, Sonoo M, Sakai M, Takada K, Harasawa A, Takeshita K, Kohtake H, Tanaka H, Suzuki S. New and reliable MRI diagnosis for progressive supranuclear palsy. *Neurology*. 2005;64(12):2050-5.
- [116] Mishina M, Ishii K, Mitani K, Ohyama M, Yamazaki M, Ishiwata K, Senda M, Kobayashi S, Kitamura S, Katayama Y. Midbrain hypometabolism as early diagnostic sign for progressive supranuclear palsy. *Acta Neurol Scand*. 2004;110(2):128-35.
- [117] Rinne JO, Iivanainen M, Metsahonkala L, Vainionpaa L, Paakkonen L, Nagren K, Helenius H. Striatal dopaminergic system in dopa-responsive dystonia: a multi-tracer PET study shows increased D2 receptors. *J Neural Transm*. 2004;111(1):59-67.
- [118] Suzuki Y, Mizoguchi S, Kiyosawa M, Mochizuki M, Ishiwata K, Wakakura M, Ishii K. Glucose hypermetabolism in the thalamus of patients with essential blepharospasm. *J Neurol*. 2007;254(7):890-6.
- [119] Amano N, Nagatomo H, Yokoi S, Yagishita S, Saitoh A, Mizutani T. [The thalamic changes in progressive supranuclear palsy]. *No to shinkei = Brain and nerve*. 1992;44(5):421-8.
- [120] Tsuboi Y, Slowinski J, Josephs KA, Honer WG, Wszolek ZK, Dickson DW. Atrophy of



superior cerebellar peduncle in progressive supranuclear palsy. *Neurology*. 2003;60(11):1766-9.

[121] Paviour DC, Price SL, Stevens JM, Lees AJ, Fox NC. Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. *Neurology*. 2005;64(4):675-9.

[122] Slowinski J, Imamura A, Uitti RJ, Pooley RA, Strongosky AJ, Dickson DW, Broderick DF, Wszolek ZK. MR imaging of brainstem atrophy in progressive supranuclear palsy. *J Neurol*. 2007: [Epub ahead of print]

[123] Fulham MJ, Brooks RA, Hallett M, Di Chiro G. Cerebellar diaschisis revisited: pontine hypometabolism and dentate sparing. *Neurology*. 1992;42(12):2267-73.

## 謝辞

本研究の機会を与えて頂き、ご指導いただいた東京大学神経内科 辻 省次教授に深謝いたします。高齢者ブレインバンクの症例提供、病理学的検索を中心に広範にご指導を頂いた東京都老人総合研究所老年病のゲノム解析研究チーム 村山繁雄先生、東京都老人医療センター剖検病理科 齊藤祐子先生に深謝します。

臨床所見についてご指導頂いた東京都老人医療センター 金丸和富先生、東京大学神経内科 清水 順に深謝します。症例の全身病理所見についてご指導いただいた東京都老人医療センター剖検病理科 沢辺元司先生に深謝します。MRI 所見についてご指導いただいた東京都老人医療センター放射線科 徳丸阿耶先生に深謝します。PET 所見についてご指導いただいた東京都老人総合研究所附属ポジトロン医学研究施設 石井賢二先生に深謝します。免疫プロットについてご指導いただいた東京都精神医学総合研究所分子神経生物学研究チーム 長谷川成人先生、抗4リピータウ抗血清を提供頂き、またご助言を頂いた大阪市立大学医学系研究科脳神経医学 森 啓教授に深謝します。MAPT 遺伝子解析についてご指導を頂いた東京大学神経内科 高橋祐二先生、後藤 順先生に深謝します。論文執筆にあたり、ご指導を頂いた東京大学 郭 伸 准教授に深謝します。

標本作成および一般・特殊染色、免疫染色についてアドバイスを頂いた東京都老人総合研究所 愛敬直雄様、原田三枝子様、直井 信子様、東京大学医学部附属病院電子顕微鏡研究室 福田 覚先生に深謝します。高齢者ブレインバンクの同僚、東京大学神経内科の皆様にも深謝いたします。

最後に、支えてくれた家族に深謝いたします。